How Alirocumab (Praluent) Affects ApoB Levels
Alirocumab (Praluent) reduces apolipoprotein B (ApoB) by 36 to 54% in clinical trials. Learn the mechanism, timeline, key trial data from ODYSSEY OUTCOMES, and when to monitor ApoB on Praluent.
Read clinical review